Tumor Mutational Burden as a Prognostic Biomarker for Relapse-Free Survival in Hepatocellular Carcinoma: Insights from Long-Term Follow-Up

High TMB is associated with shorter RFS in HCC, particularly among patients with long-term follow-up, indicating an increased risk for multicentric recurrence. TMB may serve as a valuable prognostic biomarker for recurrence risk stratification. The associations between TMB, liver fibrosis, and inflammation suggest potential therapeutic strategies targeting the hepatic microenvironment to reduce recurrence risk in patients undergoing liver resection for HCC.

Authors

Institutions

Publication Details

Journal
Liver Cancer
Published
2025-08-15
DOI
https://doi.org/10.1159/000547996
Citations
1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
1.32
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumor Mutational Burden as a Prognostic Biomarker for Relapse-Free Survival in Hepatocellular Carcinoma: Insights from Long-Term Follow-Up

Ken D Yamaguchi, Katsuhiko Uesaka, Kenichi Urakami, Hideyuki Dei et al.
1 citations
Liver Cancer
Hepatocellular Carcinoma Treatment and Prognosis
1.32
article

Tumor Mutational Burden as a Prognostic Biomarker for Relapse-Free Survival in Hepatocellular Carcinoma: Insights from Long-Term Follow-Up

Ken D Yamaguchi, Katsuhiko Uesaka, Kenichi Urakami, Hideyuki Dei, Ryo Ashida, Yukiyasu Okamura, Teiichi Sugiura, Yoshiyasu Kato, Shimpei Otsuka, Takeshi Nagashima, Keiichi Hatakeyama, Yuya Miura, Yasuto Akiyama, Keiichi Ohshima, Katsuhisa Ohgi
article en
1 citations

Abstract

High TMB is associated with shorter RFS in HCC, particularly among patients with long-term follow-up, indicating an increased risk for multicentric recurrence. TMB may serve as a valuable prognostic biomarker for recurrence risk stratification. The associations between TMB, liver fibrosis, and inflammation suggest potential therapeutic strategies targeting the hepatic microenvironment to reduce recurrence risk in patients undergoing liver resection for HCC.

Liver Cancer
Nihon University (JP), Shizuoka Cancer Center (JP), SRL (Japan) (JP)
Openalex Percentile: Top 17%
Hepatocellular Carcinoma Treatment and Prognosis
1.32
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Tumor Mutational Burden as a Prognostic Biomarker for Relapse-Free Survival in Hepatocellular Carcinoma: Insights from Long-Term Follow-Up — Ken D Yamaguchi, Katsuhiko Uesaka, et al. · Liver Cancer (2025) | TGRS Research Map | TGRS